Pharmaceutical Investing News

Pharmaceutical Investing

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

Pharmaceutical Investing

PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over 6 months, until the end of June 2018, and may be further extended. As quoted in the press release: The …

PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over 6 months, until the end of June 2018, and may be further extended.
As quoted in the press release:

The pharma company is one of the global leaders in nucleic acid therapeutics. The aim of the extension is to further evaluate the synergistic effects of both parties’ technology platforms and to determine whether PCI Biotech’s fimaNAc technology has the potential to enhance the therapeutic effect of the partner’s nucleic acid therapeutic compounds.

Click here to read the full press release.

cancerpreclinical researchtherapeuticstop 10Pharmaceutical Investing

MARKETS

Markets
TSX19222.74-35.58
TSXV644.91-7.45
DOW30946.99-491.27
S&P 5003821.55-78.56
NASD11181.54-343.01
ASX6763.60+57.60

COMMODITIES

Commodities
Gold1821.95+3.38
Silver20.85+0.03
Copper3.74-0.04
Palladium1916.35+47.35
Platinum920.00+10.00
Oil111.24-0.52
Heating Oil4.09-0.03
Natural Gas6.68+0.11

DOWNLOAD FREE REPORTS

Browse more resource reports ≫
Browse more technology reports ≫
Browse more life science reports ≫

BROWSE COMPANIES BY SECTOR

×